Your browser doesn't support javascript.
loading
Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.
Badar, Talha; Szabo, Aniko; Dinner, Shira; Liedtke, Michaela; Burkart, Madelyn; Shallis, Rory M; Yurkiewicz, Ilana R; Kuo, Eric; Khan, Muhammad Ali; Balasubramanian, Suresh; Yang, Jay; Hefazi, Mehrdad; Podoltsev, Nikolai; Patel, Anand; Curran, Emily; Wang, Amy; Arslan, Shukaib; Aldoss, Ibrahim; Siebenaller, Caitlin; Mattison, Ryan J; Litzow, Mark R; Wadleigh, Martha; Advani, Anjali S; Atallah, Ehab.
Afiliación
  • Badar T; Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Szabo A; Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Dinner S; Robert H. Lurie Comprehensive Cancer Center, Northwestern Hospital, Chicago, Illinois.
  • Liedtke M; Stanford University Cancer Center, Stanford, California.
  • Burkart M; Robert H. Lurie Comprehensive Cancer Center, Northwestern Hospital, Chicago, Illinois.
  • Shallis RM; Section of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
  • Yurkiewicz IR; Stanford University Cancer Center, Stanford, California.
  • Kuo E; Stanford University Cancer Center, Stanford, California.
  • Khan MA; Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Balasubramanian S; Karmanos Cancer Institute, Detroit, Michigan.
  • Yang J; Karmanos Cancer Institute, Detroit, Michigan.
  • Hefazi M; Division of Hematology, Mayo Clinic, Rochester, Minnesota.
  • Podoltsev N; Section of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
  • Patel A; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois.
  • Curran E; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois.
  • Wang A; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois.
  • Arslan S; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California.
  • Aldoss I; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California.
  • Siebenaller C; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
  • Mattison RJ; Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin.
  • Litzow MR; Division of Hematology, Mayo Clinic, Rochester, Minnesota.
  • Wadleigh M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Advani AS; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
  • Atallah E; Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
Cancer ; 127(7): 1039-1048, 2021 04 01.
Article en En | MEDLINE | ID: mdl-33259056
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Anticuerpos Biespecíficos / Leucemia-Linfoma Linfoblástico de Células Precursoras / Antineoplásicos Inmunológicos / Inotuzumab Ozogamicina Tipo de estudio: Observational_studies Idioma: En Revista: Cancer Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Anticuerpos Biespecíficos / Leucemia-Linfoma Linfoblástico de Células Precursoras / Antineoplásicos Inmunológicos / Inotuzumab Ozogamicina Tipo de estudio: Observational_studies Idioma: En Revista: Cancer Año: 2021 Tipo del documento: Article